Legal Representation
Attorney
Laurence Tauber
USPTO Deadlines
Next Deadline
532 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2017-01-03)
Due Date
January 03, 2027
Grace Period Ends
July 03, 2027
Application History
43 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Sep 8, 2023 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
Sep 8, 2023 | C15A | O | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | Loading... |
Sep 8, 2023 | NA85 | E | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | Loading... |
Mar 10, 2023 | E815 | I | TEAS SECTION 8 & 15 RECEIVED | Loading... |
Jan 3, 2022 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
Jan 11, 2017 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
Jan 11, 2017 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
Jan 3, 2017 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
Oct 18, 2016 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Oct 18, 2016 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Sep 28, 2016 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Sep 14, 2016 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
Sep 1, 2016 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Aug 31, 2016 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
Aug 31, 2016 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
Aug 31, 2016 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
Aug 31, 2016 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
Aug 15, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Aug 15, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Aug 13, 2016 | ALIE | A | ASSIGNED TO LIE | Loading... |
Aug 5, 2016 | NREV | E | NOTICE OF REVIVAL - E-MAILED | Loading... |
Aug 4, 2016 | PROA | I | TEAS PETITION TO REVIVE RECEIVED | Loading... |
Aug 4, 2016 | PETG | O | PETITION TO REVIVE-GRANTED | Loading... |
Aug 4, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Jul 18, 2016 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
Jul 18, 2016 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Feb 3, 2016 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Feb 3, 2016 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
Feb 3, 2016 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Jan 20, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Jan 20, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Jan 20, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Jul 21, 2015 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Jul 21, 2015 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
Jul 21, 2015 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Jul 20, 2015 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Jul 20, 2015 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Jul 20, 2015 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Jul 14, 2015 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Apr 30, 2015 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
Apr 30, 2015 | TAEA | I | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | Loading... |
Apr 14, 2015 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Apr 9, 2015 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceuticals, namely, prescription and over-the-counter drugs for the treatment of illness, disease or deficiencies, namely, bacterial infections, treatment symptoms of seasonal, perennial and chronic allergies and the treatment of skin hives and itching associated with skin reactions, Type 2 diabetes mellitus, Treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid induced osteoporosis, Treatment of Paget's Disease of bone, Treatment for the relief of discomfort associated with acute or painful musculoskeletal conditions, Treatment and management of moderate to moderately-severe pain in adults, Treatment of hypertension, Treatment of diabetic nephropathy, Treatment of dermatitis herpetiformis and leprosy, Treatment of chronic inflammatory skin disease marked by blisters, Treatment of acid indigestion, Treatment of upset stomach, Management and support for patients requiring increased folate levels, Supplementation in support of bone health, Supplementation in support of prenatal health, including, without limitation, increased folic acid, Management and support of absorption of calcium and/or functioning of calcium in the body, Treatment of Vitamin D deficiency, Supplementation in support of postnatal health, Treatment and prevention of lack of vitamins, minerals and/or fatty acids during pregnancy, Treatment and temporary relief of cough, nasal congestion, loosening of phlegm and thin bronchial secretions, Treatment and prevention of prenatal and postnatal folate deficiency, Treatment of elevated or high levels of uric acid and prevention and treatment of metabolic problems caused by kidney disease, prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets, hormone replacement therapy, Postnatal supplementation and improvement of nutritional states of women prior to conception, prevention of acidosis, stomach or bowel problems, peptic ulcers and irritable bowel syndrome, Treatment for excessive saliva production, irritable colon and bladder dysfunction, Treatment of symptoms associated with disorders of gastrointestinal tract, bladder spasms, peptic ulcer disease, diverticulitis, irritable bowel syndrome, cystitis and pancreatitis, Prevention and treatment of low blood levels of potassium, Prevention of Fetal Neural Tube Defects when pregnant, Treatment of inadequate folic acid, folate deficiency, and anemia from inadequate folic acid, Treatment of Hyperhomocysteinemia
First Use Anywhere:
Oct 1, 2011
First Use in Commerce:
Oct 1, 2011
Class 035
Distributorship services in the field of prescription and over-the-counter drugs; marketing of prescription and over-the-counter drugs
First Use Anywhere:
Oct 1, 2011
First Use in Commerce:
Oct 1, 2011
Class 042
Development of pharmaceutical products
First Use Anywhere:
Oct 1, 2011
First Use in Commerce:
Oct 1, 2011
Classification
International Classes
005
035
042